ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal

ADC Therapeutics will receive $225 million in cash and an additional $100 million in near-term milestones as part of a royalty sale with HealthCare Royalty for its lead antibody-drug conjugate Zynlonta and investigational CD25 candidate camidanlumab tesirine (Cami), the companies said Thursday.